Skip to main
EXEL
EXEL logo

Exelixis (EXEL) Stock Forecast & Price Target

Exelixis (EXEL) Analyst Ratings

Based on 28 analyst ratings
Buy
Strong Buy 39%
Buy 25%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

Exelixis Inc continues to show robust growth, particularly with its cabozantinib (Cabo) franchise, which reported 20% year-over-year growth in the fourth quarter, amounting to $515.2 million in net product revenue for FY 2024. The company's strategic positioning in the metastatic renal cell carcinoma (RCC) market, along with a positive survey suggesting a significant demand for Cabo among oncologists treating advanced neuroendocrine tumors (NETs), indicates considerable upside potential for the treatment. Additionally, Exelixis is projected to achieve over $2 billion in revenue by 2025, bolstered by anticipated expansions in market penetration and the ongoing development of zanzalintinib.

Bears say

Exelixis Inc is facing significant risks that could adversely impact its stock outlook, primarily stemming from anticipated declines in market share for cabozantinib across various cancer settings due to potential failures in clinical programs, particularly regarding zanzalintinib. The company's revenue guidance appears conservative, not factoring in potential contributions from neuroendocrine tumors (NETs), which may signify future financial strain if the product fails to meet market expectations. Furthermore, the company's critical clinical data and ongoing developments indicate concerns over tolerability and competitive positioning that could further dilute its market presence, leading to negative long-term outlooks.

Exelixis (EXEL) has been analyzed by 28 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 25% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Exelixis (EXEL) Forecast

Analysts have given Exelixis (EXEL) a Buy based on their latest research and market trends.

According to 28 analysts, Exelixis (EXEL) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Exelixis (EXEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.